CD44 and ovarian carcinoma: In addition, our survival analysis showed that CD44 expression is slightly associated with a better prognosis for ovarian cancer cases and for the PD-L1 negative ovarian cancer (HR = 1.6, 95% CI [0.7–3.7] and (HR = 2.4, 95% CI.